Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Discontinued Operations (2016)

Historic Cash from Discontinued Operations for Ligand Pharmaceuticals (LGND) over the last 4 years, with Q4 2016 value amounting to -$1.1 million.

  • Ligand Pharmaceuticals' Cash from Discontinued Operations changed N/A to -$1.1 million in Q4 2016 from the same period last year, while for Jun 2017 it was -$1.1 million, marking a year-over-year decrease of 20000.0%. This contributed to the annual value of -$642000.0 for FY2013, which is 2866.67% up from last year.
  • As of Q4 2016, Ligand Pharmaceuticals' Cash from Discontinued Operations stood at -$1.1 million.
  • Ligand Pharmaceuticals' 5-year Cash from Discontinued Operations high stood at $1.1 million for Q1 2016, and its period low was -$1.1 million during Q4 2016.
  • Over the past 3 years, Ligand Pharmaceuticals' median Cash from Discontinued Operations value was -$350000.0 (recorded in 2012), while the average stood at -$257000.0.
  • Examining YoY changes over the last 5 years, Ligand Pharmaceuticals' Cash from Discontinued Operations showed a top increase of 22100.0% in 2013 and a maximum decrease of 22100.0% in 2013.
  • Ligand Pharmaceuticals' Cash from Discontinued Operations (Quarter) stood at -$350000.0 in 2012, then crashed by 83.43% to -$642000.0 in 2013, then plummeted by 77.41% to -$1.1 million in 2016.
  • Its Cash from Discontinued Operations stands at -$1.1 million for Q4 2016, versus $1.1 million for Q1 2016 and -$642000.0 for Q1 2013.